Nephrology
-
Randomized Controlled Trial Multicenter Study
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
While darbepoetin alfa (DA) can be administered once monthly (QM) to maintain haemoglobin (Hb) concentrations in anaemic patients with chronic kidney disease not on dialysis (CKD-ND), the QM use of DA for anaemia correction has not been previously investigated. ⋯ In subjects with CKD-ND, QM dosing was non-inferior to Q2W dosing for anaemia correction and had a similar safety profile.
-
Very little data exist regarding community-acquired acute renal injury (CA-AKI). We have identified and characterized a patient cohort with CA-AKI, and documented its impact on renal function and patient mortality. ⋯ CA-AKI carries significant implications in terms of both development of progressive renal disease and high long-term patient mortality.
-
We investigated the diagnostic performance of urinary kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) for acute kidney injury (AKI) in 90 obstructive nephropathy patients. ⋯ Urinary KIM-1 and NGAL had a good accuracy for detecting AKI. KIM-1 72 h postoperatively can predict the renal outcome of obstructive nephropathy.
-
Early intervention in patients with chronic kidney disease (CKD) significantly improves the prognosis. The present widely used markers of renal function, such as serum creatinine (sCr), fail to reflect early renal damage and predict the progression of disease. The authors aimed to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL), a novel specific biomarker of acute kidney injury, could predict the progression of CKD. ⋯ Serum NGAL is an effective biomarker for detecting early-stage renal damage in CKD patients. Serum NGAL was significantly correlated with the severity of renal damage and the progression of renal function deterioration.